Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
MWN-AI** Summary
Adagio Medical Holdings, Inc. is set to showcase its innovative Ultra-low Temperature Ablation (ULTA) technologies at the upcoming Heart Rhythm 2026 conference from April 23 to April 26 in Chicago. This groundbreaking approach targets scar-related ventricular tachycardias—a critical area of focus given the challenges in treating these complex arrhythmias.
During the conference, Adagio will host multiple presentations highlighting the efficacy and safety of its ULTA technologies. Notable sessions include presentations by Dr. Druv Sharma on the use of ultra-low temperature cryoablation in inaccessible ventricular tachycardia cases and Dr. Travis Richardson on acute outcomes from the FULCRUM-VT clinical trial, illustrating the system’s real-world applications. Additionally, a late-breaking session will present pivotal FULCRUM-VT trial outcomes, underscoring ULTA’s effectiveness in patients with structural heart disease.
Adagio’s ULTA technology utilizes a proprietary catheter-based cryoablation system designed to create durable lesions in both diseased and healthy cardiac tissues. This method is considered essential for the endocardial treatment of ventricular arrhythmias, potentially changing the landscape of cardiac intervention. With the vCLAS™ Cryoablation System, which holds CE marking in Europe but is still under investigation for FDA premarket approval in the U.S., Adagio aims to establish a broad indication for the purely endocardial ablation of scar-mediated ventricular tachycardia.
The FULCRUM-VT trial illustrates Adagio's commitment to advancing arrhythmia care with robust clinical data, highlighting the promising trajectory for ULTA technologies in both clinical and practical settings. The Heart Rhythm 2026 conference will serve as a key platform for Adagio to connect with leading cardiologists and industry peers, enhancing awareness and understanding of its pioneering technologies.
MWN-AI** Analysis
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is poised for a significant moment at the upcoming Heart Rhythm 2026 conference, where its innovative Ultra-Low Temperature Ablation (ULTA) technology will take center stage. This product addresses a critical need in the treatment of scar-related ventricular tachycardia (VT), a condition that can be life-threatening and difficult to manage. The featured presentations represent a strong endorsement of ULTA’s potential, demonstrating real-world clinical applications and promising results from the ongoing FULCRUM-VT trial.
Investors should closely monitor Adagio leading into and following the conference. With multiple presentations by esteemed clinicians from reputable institutions discussing successful outcomes and procedural insights using ULTA, the firm's visibility and credibility will likely enhance. Particularly noteworthy is the late-breaking clinical trial presentation focused on the FULCRUM-VT trial results, which could be a pivotal moment for the company. Positive results here may not only boost investor confidence but also pave the way for FDA premarket approval, significantly expanding Adagio's market potential in the U.S.
Currently, Adagio’s vCLAS™ Cryoablation System is CE Marked and in investigational use in the U.S. The possibility of flipping this status post-conference could unlock substantial revenue pathways and increase the company’s competitive edge in a growing cardiac device market, projected to reach considerable size in the coming years.
Moreover, as the healthcare sector continues shifting towards innovative, minimally invasive treatments for complex conditions, Adagio is strategically positioned to capitalize on this trend. Therefore, investors may find Adagio’s stock a compelling opportunity, especially as the Heart Rhythm 2026 conference unfolds, providing a platform for both awareness and further validation of its market-leading technology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Use of ULTA Across Broad Spectrum of Ventricular Tachycardias to be Highlighted in Multiple Scientific Presentations, Including Late-Breaking Clinical Trial Session
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra-low Temperature Ablation technologies (ULTA) for the treatment of scar-related ventricular tachycardia will be featured in several presentations at the Heart Rhythm Society's 47th Annual Scientific Sessions – Heart Rhythm 2026 conference, to be held from Thursday, April 23 to Sunday, April 26, 2026, in Chicago, Illinois at the McCormick Place Convention Center.
In addition to its booth and technology suite, Adagio’s ULTA technologies will be featured in several events and presentations:
Friday, April 24, 2026
- Ultra-Low Temperature Cryoablation for Inaccessible Ventricular Tachycardia in Right Ventricular Cardiomyopathy: First Reported Cases Using a Novel System, Presented by Dr. Druv Sharma, Vanderbilt University, 11:40–11:50 a.m., Heart Rhythm Hub 5
- Ultra-Low Ventricular Ablation Beyond Clinical Trials: Procedure and MRI Insights from Real-World Patient Series, Presented by Dr. Borislav Dinov, Justus Liebig University Giessen, Germany, 1:00 p.m. at Adagio Booth #1222
- Ultra-Low Temperature Cryoablation of Periaortic Ventricular Tachycardia in Nonischemic Cardiomyopathy: Acute Outcomes from FULCRUM-VT Trial (FP-53573), Presented by Dr. Travis Richardson, Vanderbilt University, 3:15–5:15 p.m., Abstracts Pavilion
- After Hours Case-Based Panel Discussion: Challenges, Hurdles and New Technology Opportunities in Ventricular Ablation, Moderator: Dr. William Stevenson, Vanderbilt University; Panelists: Dr. Atul Verma; Dr. Roderick Tung; Dr. Gregory Supple; Dr. Jeffrey Winterfield; Dr. Mark Gallagher; Dr. Borislav Dinov, 5:30–7:00 p.m. at Adagio Booth #1222
Saturday, April 25, 2026
- Acceleration of Ultra-Low Temperature Ventricular Ablation with Next-Generation Technology: Insights from Pre-Clinical Studies, Presenter: Dr. Katia Dyrda, Montreal Heart Institute, 10:00 a.m ., Adagio Booth #1222
- VT Ablation Using Ultralow Cryoablation (AB-532086), Presenter: Dr. Travis Richardson, Vanderbilt University, 11:00–11:12 a.m., Hub 1
- Ultra-Low Temperature Cryoablation of Ventricular Tachycardia due to Ischemic and Nonischemic Cardiomyopathy: Acute Outcomes of FULCRUM-VT Trial (PO-535640), Presenter: Dr. Travis Richardson, Vanderbilt University, 12:00–2:00 p.m., Abstracts Pavilion
- Acute and Mid-term Efficacy of Ultralow Temperature Cryotherapy for Ablation of Ventricular Ectopics (PO-536440), Presenter: Dr. Jaspal Singh Gill, St. George’s Hospital, 12:00–2:00 p.m., Abstracts Pavilion
- Imaging-Guided Scar Assessment Determines Duration of Ultra-Low Temperature Cryoablation for VT Procedures: FULCRUM-VT Substudy (PO-536440), Presenter: Dr. Bishnu Dhakal, Medical University of South Carolina, 12:00–2:00 p.m., Abstracts Pavilion
- Emerging Role of Ultra-Low Temperature Ablation in Management of Periaortic and Right Ventricular VTs (Case-Based Review), Presenters: Dr. William Stevenson and Dr. Hari Tandri, Vanderbilt University, 1:25 p.m. Adagio Booth #1222
- Ultra-Low Ventricular Ablation Beyond Clinical Trials: Procedure and MRI Insights from Real-World Patient Series, Presenter: Dr. Borislav Dinov, 2:55 p.m. Adagio Booth #1222
- Ultra-Low Temperature Ventricular Ablation in Complex Cases – After or Before Everything Else Fails? (Case-Based Review), Presenter: Dr. Gregory Supple, University of Pennsylvania, 4:15 p.m. Adagio Booth #1222
Sunday, April 26, 2026: Late-Breaking Clinical Trial Presentation
- Effectiveness and Safety of Ultra-Low Temperature Ablation of Ventricular Tachycardia in Patients with Structural Heart Disease: Outcomes of the Pivotal FULCRUM-VT Trial, Presenter: Dr. Atul Verma, McGill University Health Centre; Co-Principal Investigator, 8:30 a.m., Room S100c
About Adagio Medical Holdings, Inc.
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA, formerly known as ULTC) technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.
About FULCRUM VT
FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for U.S. Food and Drug Administration (FDA) premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.
Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260416240050/en/
Debbie Kaster
Chief Financial Officer and Chief Business Officer
dkaster@adagiomedical.com
FAQ**
How does Adagio Medical Holdings Inc ADGM plan to leverage the findings from the FULCRUM-VT trial to gain FDA premarket approval for its vCLAS™ Cryoablation System?
What specific data will be presented at the Heart Rhythm 20conference related to the effectiveness of ULTA technologies from Adagio Medical Holdings Inc ADGM?
In what ways does Adagio Medical Holdings Inc ADGM's ULTA technology differentiate itself from existing treatments for ventricular tachycardia?
How does Adagio Medical Holdings Inc ADGM intend to address potential challenges and hurdles in the commercialization of its ULTA technologies following the presentations at Heart Rhythm 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Adagio Medical Holdings Inc (NASDAQ: ADGM).
NASDAQ: ADGM
ADGM Trading
-1.32% G/L:
$0.7401 Last:
30,780 Volume:
$0.732 Open:
